We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunoassay for Earlier Diagnosis of Neonatal Sepsis to Enable Appropriate Interventions

By LabMedica International staff writers
Posted on 20 Oct 2023
Print article
Image: IL-6 is the first immunoassay approved to aid sepsis diagnosis in newborns (Photo courtesy of Roche)
Image: IL-6 is the first immunoassay approved to aid sepsis diagnosis in newborns (Photo courtesy of Roche)

Neonatal sepsis is a bloodstream infection that occurs in the first four weeks of a baby's life, and it comes with significant risks for severe illness or death. Because it often starts with vague symptoms but can quickly escalate to multiple organ failure, early detection and timely treatment are crucial. Babies with this condition don't usually show clear symptoms, making early diagnosis challenging. Measuring levels of IL-6 (interleukin-6) has proven useful in diagnosing neonatal sepsis early. IL-6 levels rise quickly in response to infection, quicker than other indicators, making it an effective early alert for inflammation, infection, or sepsis. Timely diagnosis allows healthcare providers to take immediate and suitable action, improving the chances for a good outcome for the newborn.

Roche’s (Basel, Switzerland) Elecsys IL-6 immunoassay is the first IL-6 test to be certified for use in the diagnosis of neonatal sepsis in countries accepting the CE Mark. The vitro diagnostic test quantitatively measures IL-6 levels in human blood serum and plasma. It helps doctors by enabling quicker identification of severe inflammatory responses, thereby speeding up the diagnosis of neonatal sepsis.

Faster diagnosis allows medical professionals to take quicker and more effective steps to improve the baby's prospects. The Elecsys IL-6 immunoassay is especially practical as it takes just 18 minutes to complete and requires only a small blood sample. Designed as an electrochemiluminescence immunoassay (ECLIA), the Elecsys IL-6 test is intended for use with cobas e immunoassay analyzers.

“Sepsis is one of the leading causes of death in newborns and we need to do everything we can to prevent these deaths," said Matt Sause, CEO of Roche Diagnostics. "Receiving the first approval for IL-6 use with newborns, is a significant step forward in helping clinicians confidently diagnose neonatal sepsis earlier and save more lives.”

Related Links:
Roche

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
Nutating Mixer
Enduro MiniMix

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more